• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Omega Healthcare Investors Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/11/25 5:29:59 PM ET
    $OHI
    Real Estate Investment Trusts
    Real Estate
    Get the next $OHI alert in real time by email
    false 0000888491 0000888491 2025-06-10 2025-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 10, 2025

     

    OMEGA HEALTHCARE INVESTORS, INC.

    (Exact name of registrant as specified in its charter)

     

    Maryland 1-11316 38-3041398
    (State or other jurisdiction of
    incorporation)
    (Commission File Number)

    (IRS Employer

    Identification No.)

     

    303 International Circle

    Suite 200

    Hunt Valley, Maryland 21030

    (Address of principal executive offices / Zip Code)

     

    (410) 427-1700

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ¨ Written communications pursuant to Rule 425 under the Securities Act.

     

      ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

     

      ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

     

      ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

     

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

         
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $.10 par value OHI New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 8.01 Other Events.

     

    On June 10, 2025, Omega Healthcare Investors, Inc. (“Omega”) issued a press release announcing the pricing of an underwritten public offering (the “Offering”) of $600,000,000 aggregate principal amount of 5.200% Senior Notes due 2030. The press release announcing the pricing of the Offering is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

      

    Also on June 10, 2025, Omega entered into an underwriting agreement (the “Underwriting Agreement”) with the representatives of the several underwriters named therein relating to the Offering. The net proceeds from the Offering, after deducting the underwriting discount but before deducting estimated Offering expenses payable by Omega, are expected to be approximately $591,108,000, which Omega intends to use for general corporate purposes, which may include, among other things, repayment of existing indebtedness and future acquisition or investment opportunities in healthcare-related real estate properties and to pay certain fees and expenses related to the Offering.

     

    The foregoing is a summary description of certain terms of the Underwriting Agreement and is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits. The following exhibits are being filed herewith:

     

    No.   Description
    1.1   Underwriting Agreement, dated June 10, 2025, by and among Omega and the representatives of the underwriters named therein
    99.1   Press Release, dated June 10, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      OMEGA HEALTHCARE INVESTORS, INC.
         
    Dated: June 11, 2025 By: /s/ Robert O. Stephenson
      Name: Robert O. Stephenson
      Title: Chief Financial Officer

     

     

    Get the next $OHI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OHI

    DatePrice TargetRatingAnalyst
    3/27/2025$41.00 → $39.00Overweight → Equal Weight
    Wells Fargo
    12/9/2024$45.00Market Perform → Outperform
    BMO Capital Markets
    10/31/2024$49.00Neutral → Outperform
    Exane BNP Paribas
    10/18/2024$45.00Buy
    Berenberg
    7/25/2024$34.00 → $35.00Outperform → Neutral
    Mizuho
    3/22/2024$32.00 → $35.00Neutral → Buy
    Citigroup
    2/26/2024$31.00 → $35.00Equal Weight → Overweight
    Wells Fargo
    2/8/2024$30.00Underperform → Neutral
    Exane BNP Paribas
    More analyst ratings